focus -WSS

focus

author：entertainment 2025-10-01 05:23:50 - browse：6969

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Arena BioWorks launches in Cambridge to speed drug discovery

WSS

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Merck to acquire Harpoon Therapeutics for $680 million

Ascension's ugly legal battle over care for poor patients in Texas

'Cuddling' is just what the doctor ordered for a 200

Male doctors called my cancer incurable. A female doctor showed it wasn't

Merck to acquire Harpoon Therapeutics for $680 million

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Peter Hotez and the public health issue of online harassment

Study suggests new cause of Down syndrome: cells linked to aging

BioMarin wins approval for gene therapy to treat hemophilia A

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Heart attack and stroke risk calculators need revising

Physician assistants need a new name. Here's what it should be

How one medical school became remarkably diverse

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

Activists slam private health insurers over coverage restrictions

FDA early review: GLP

focus

Medicare Advantage coverage denials need scrutiny, senators say

In shift, Texas to cover initial consult for Afghan baby's gene therapy

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

Medicare Advantage coverage denials need scrutiny, senators say

American taxpayers paid $1.8 trillion in health care costs in 2022

entertainment

focus

focus

entertainment